Peptidyl ketones as inhibitors of DPIV

Details Peptidyl ketones as inhibitors of DPIV Peptidyl ketones as inhibitors of DPIV

2002-08-09

2009-10-27

Kosar, Andrew D (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C530S300000, C530S333000, C530S345000

Reexamination Certificate

active

07608577

ABSTRACT:
The present invention relates to compounds of the general formula 1and pharmaceutically acceptable salts thereof, to the use of the compounds for the treatment of impaired glucose tolerance, glucosuria, hyperlipidaemia, metabolic acidosis, diabetes mellitus, diabetic neuropathy and nephropathy and of sequelae caused by diabetes mellitus in mammals.

REFERENCES:
patent: 2961377 (1960-11-01), Shapiro et al.
patent: 3174901 (1965-03-01), Sterne
patent: 3879541 (1975-04-01), Kabbe et al.
patent: 3960949 (1976-06-01), Ahrens et al.
patent: 4028402 (1977-06-01), Fischer et al.
patent: 4643991 (1987-02-01), Digenis et al.
patent: 4935493 (1990-06-01), Bachovchin et al.
patent: 5008245 (1991-04-01), Digenis et al.
patent: 5162307 (1992-11-01), Digenis et al.
patent: 5433955 (1995-07-01), Bredehorst et al.
patent: 5462928 (1995-10-01), Bachovchin et al.
patent: 5512549 (1996-04-01), Chen et al.
patent: 5543396 (1996-08-01), Powers et al.
patent: 5614379 (1997-03-01), MacKellar
patent: 5624894 (1997-04-01), Bodor
patent: 5639783 (1997-06-01), Ando et al.
patent: 5834508 (1998-11-01), Ando et al.
patent: 5922319 (1999-07-01), Digenis et al.
patent: 5939560 (1999-08-01), Jenkins et al.
patent: 6006753 (1999-12-01), Efendic
patent: 6319893 (2001-11-01), Demuth et al.
patent: 2001/0020006 (2001-09-01), Demuth et al.
patent: 25 42 598 (1976-04-01), None
patent: 296 075 (1991-11-01), None
patent: 196 16 486 (1997-10-01), None
patent: 299 09 210 (1999-09-01), None
patent: 198 26 972 (1999-12-01), None
patent: 0 658 568 (1995-06-01), None
patent: 0 708 179 (1996-04-01), None
patent: 2 085 665 (1971-12-01), None
patent: 2 696 740 (1994-04-01), None
patent: 04-288098 (1992-10-01), None
patent: 4334357 (1992-11-01), None
patent: WO 91/11457 (1991-08-01), None
patent: WO 91/16339 (1991-10-01), None
patent: WO 91/17767 (1991-11-01), None
patent: WO 93/08259 (1993-04-01), None
patent: WO 95/11689 (1995-05-01), None
patent: WO 95/15309 (1995-06-01), None
patent: WO 95/29691 (1995-11-01), None
patent: WO 97/40832 (1997-11-01), None
patent: WO 97/45117 (1997-12-01), None
patent: WO 98/19998 (1998-05-01), None
patent: WO 98/22494 (1998-05-01), None
patent: WO 99/46272 (1999-09-01), None
patent: PCT/EP99/04381 (1999-12-01), None
patent: WO 99/62914 (1999-12-01), None
patent: WO 00/01849 (2000-01-01), None
patent: WO 00/10549 (2000-03-01), None
patent: WO 00/53171 (2000-09-01), None
patent: WO 01/34594 (2001-05-01), None
patent: WO 01/62266 (2001-08-01), None
patent: WO 01/74299 (2001-10-01), None
patent: WO 01/89569 (2001-11-01), None
patent: WO 01/97808 (2001-12-01), None
patent: WO 02/20825 (2002-03-01), None
S Tsutsumi, et al. Synthesis and structure-activity relationships of peptidyl alpha-keto heterocycles as novel inhibitors of prolyl endopeptidase. (1994) J. Med. Chem. 37, 3492-3502.
P. Walther and W. Grondler. Studia Biophysica (1983) 96(3), pp. 235-236.
Fittkau, et al. Biomedica Biochmica Acta (1984) 43(7), pp. 887 -899.
S. Fittkau, et al. Biomed. Biochim. Acta (1984) 43(7), pp. 887-899. English Translation, 26 pages.
F. Rypacek, et al. J. Med. Chem. (1994) 37, pp. 1850-1856.
M. Kato et al. J. Enzyme Inhibition. (1993) 7, pp. 105-130.
R. Joyeau et al. Eur. J. Med. Chem. (2000) 35, pp. 257-266.
Campbell, I.W.New Antidiabetic Drugs, ed. C.J. Bailey & P.R. Flatt, Smith-Gordon, “Sulphonylureas and metformin: efficacy and inadequacy”. 3:33-51 (1990).
The Merck Index, 11thEdition,An Encyclopedia of Chemicals. Drugs, and Biologicals, 1989, p. 934.
The Merck Index, 12thEdition,An Encyclopedia of Chemicals, Drugs, and Biologicals, 1996, p. 1014.
Martindale The Extra Pharmacopoeia, 30thEdition, London Pharmaceutical Press, 1993, p. 1619.
Martindale The Extra Pharmacopoeia, 30thEdition, London Pharmaceutical Press, 1993, p. 36.
Chemical Abstracts, vol. 115. No. 15, Oct. 14, 1991 Columbus, Ohio, US; abstract No. 149947q, Schoen Ekkehard et al: “Dipeptidyl peptidase IV in the immune system. Effects of specific enzyme inhibitors on activity of dipeptidyl peptidase IV and proliferation of human lymphocytes”.
Chemical Abstracts, vol. 126, No. 2, Jan. 13, 1997 Columbus, Ohio, US; abstract No. 16161j, Stoeckel A. et al: “Competitive inhibition of proline specific enzymes by amino acid thioxopyrrolidides and thiazolidides”.
Chemical Abstracts, vol. 118, No. 25, Jun. 21, 1993 Columbus, Ohio, US; abstract No. 255342k, Hosoda, et al, “Preparation of N-(heterocyclic Carbonyl) Amino Acids and Analogs as Prolyl Endopeptidase Inhibitors”, (Nov. 20, 1992).
Arai et al., “Synthesis of prolyl endopeptidase inhibitors and evaluation of their structure-activity relationships : in vitro inhibition of prolyl endopeptidase from Canine Brain”Chemical and Pharmaceutical Bulletin., Bd. 41, No. 9, 1993, pp. 1583-1588.
J. Lin et al.: “Inhibition of depeptidyl peptidase IV by fluoroolefin-containing n-peptidy1-O-hydroxylamine peptidomimetics”Proceedings of the National Academy of Sciences of USA, vol. 95, Nov. 1998, pp. 14020-14024.
Korom, S., et al “Inhibition of CD26/dipeptidyl peptidase IV activity in vivo prolongs cardiac allograft survival in rat recipients”, Transplantation, vol. 63, 1495-1500 No. 10 (1997).
Tanka, S., et al., “Suppression of arthritis by the inhibitors of dipeptidyl peptidase IV”.Int. J. Immunopharmacol, vol. 19, No. 1 pp. 15-24, (1997).
Mentlein, R., et al., “Proteolytic processing of neuropeptide Y and peptide YY by dipeptidyl peptidase IV”.Regul. Pept. 49, 133-144 (1993).
Wetzel, W., et al., “Effects of the CLIP fragment ACTH 20-24 on the duration of REM sleep episodes”.Neuropeptides, 31, 41-45 (1997).
Amasheh, S., et al., “Electrophysiological analysis of the function of the mammalian renal peptide transporter expressed in Xenopus Laevis oocytes”.J. Physiol.504, 169-174 (1997).
Durinx, C.; et al.; “Reference Values for Plasma Dipepidyl-Pepidase IV activity and their Association with Other Laboratory Parameters”.Clin Chem Lab Med 2001, February; 39 (2) :155-9, 1 page, Abstract Only.
Gossrau, R.; “Cytochemistry of Membrane Proteases”.Histochem J, Jul. 1985; 17 (7) :737-71, 1 page, Abstract Only.
Hahn, T.; et al.; “Enzyme Histochemical Evidence for the Presence of Potential Blood Regulating Proteases in Cultured Villous Explants from Human First Trimester Placentae”.Acta HistochemDec. 1993, 95 (2) :185-92, 1 page, Abstract Only.
Heymann, E. et al., “Has Dipeptidyl Peptidase IV an Effect on Blood Pressure and Coagulation.”Klin Wochenscher, Jan. 1984, 2;62 (1) :2-10, 1 page, Abstract Only.
Magyar, C.E. et al., “Proximal Tubule Na Transporter Responses are the same during Acute and Chronic Hypertension.”Am J. Physiol Renal Physiol, Aug. 2000; 279 (2) :F358-69, 1 page, Abstract Only.
Papies, B. et al., “Isoenzyme (Lactate Dehydrogenase, Aspartate Aminotransferase) and Dipeptidyl Peptidase IV Activity Changes in Blood Plasma Likely Indicative of Organ Involvement due to Arterial Hypertension.”Cor Vasa, 1991; 33 (3) :218-26, 1 page, Abstract Only.
Qureshi. N.U.; et al., “Endogenous Neuropeptide Y Mediates Vasoconstriction during Endotoxic and Hemorrhagic Shock”.Regul Pept, Sep. 25, 1998; 75-76:215-20, 1 page, Abstract Only.
Index Nominum,International Drug Directory 1992/1993, Medpharm Scientific Publishers, pp. 728-729.
The Merck Index,An Encyclopedia of Chemicals and Drugs, 9thEdition, Merck & Co., Inc., 1976, p. 773.
Willms et al., Journal of Clinical Endocrinology Metabolism, “Gastric Emptying, Glucose Responses, and Insulin Secretion after a Liquid Test Meal: Effects of Exogenous Glucagon-Like Peptide-1 (GLP-1)-(7-36) Amide in Type 2 (Noninsulin-Dependent) Diabetic Patients”, 1996, 81(1): 327-332.
Hoffmann et al.,Journal of Chromatography A, “Inhibition of dipeptidyl peptidase IV (DP IV) by anti-DP IV antibodies and non-substrate X-X-Pro- oligopeptides ascertained by capillary eletrophoresis”, 1995, 716:355-362.
C.B. Welch,Medic

Affiliated with

Also associated with

Rating

Peptidyl ketones as inhibitors of DPIV does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Peptidyl ketones as inhibitors of DPIV, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Peptidyl ketones as inhibitors of DPIV will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4125916